Clinical Trials Logo

Peripheral Neuropathy clinical trials

View clinical trials related to Peripheral Neuropathy.

Filter by:
  • Active, not recruiting  
  • « Prev · Page 2

NCT ID: NCT02166385 Active, not recruiting - Pain Clinical Trials

Pregabalin in Preventing Acute Pain Syndrome in Patients Receiving Paclitaxel

Start date: January 2012
Phase: N/A
Study type: Interventional

This randomized pilot clinical trial studies pregabalin in preventing acute pain syndrome in patients receiving paclitaxel. Pregabalin may control the pain caused by cancer treatment.

NCT ID: NCT01278225 Active, not recruiting - Pain Clinical Trials

Effects of Neurofeedback on Neural Function, Neuromodulation, and Chemotherapy-Induced Neuropathic Pain

Start date: February 2011
Phase:
Study type: Observational

The goal of this study is to learn if using a non-invasive therapy called "neurofeedback training" can help teach patients ways to modify their own brain waves to decrease the perception of pain and improve quality of life.

NCT ID: NCT00006072 Active, not recruiting - Clinical trials for Peripheral Neuropathy

A Study of Rituxan in the Treatment of Polyneuropathies Associated With Serum IgM Autoantibodies

Start date: n/a
Phase: Phase 2
Study type: Interventional

Peripheral neuropathies cause weakness and sensory loss that can produce severe disability. Some neuropathies are immune-mediated and associated with antibodies. It has been postulated that Rituxan treatment may reduce the level of antibody production limiting the loss of muscle strength and hence improve activities of daily living. The purpose of this open-label study (all participants get Rituxan and not placebo) is to determine the safety and effectiveness of Rituxan in the treatment of polyneuropathies associated with serum IgM autoantibodies in those who have already been treated with one course of Rituxan. Subjects will be treated on the in-patient Clinical Research Center with Rituxan for two treatments one week a part and then individual treatments every 10 weeks for one year. The effectiveness of Rituxan will be followed by looking for increases in muscle strength and decreases in the serum IgM autoantibodies.